“Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States”, J of Skin, vol. 9, no. 6, p. s630, Nov. 2025, doi: 10.25251/ej4zcr36.